Alnylam Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
ALNY Key Statistics
Stock Snapshot
With a market cap of 46.67B, Alnylam Pharmaceuticals(ALNY) trades at $332.68. The stock has a price-to-earnings ratio of 142.81.
As of 2026-02-19, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $324.53 and $335.80. The current price stands at $332.68, placing the stock +2.5% above today's low and -0.9% off the high.
The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 1.14M, compared to an average daily volume of 1.78M.
During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.
During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.
ALNY News
Alnylam Pharmaceuticals (NasdaqGS:ALNY) reports its first full year of profitability, supported by its TTR franchise. The company introduces a new RNAi manufac...
Alnylam Pharma, the Healthcare sector company, was revisited by a Wall Street analyst on February 13. Analyst Whitney Ijem from Canaccord Genuity maintained a B...
Canaccord raised the firm’s price target on Alnylam (ALNY) to $429 from $415 and keeps a Buy rating on the shares. The firm updated its model following Q4 resul...
Analyst ratings
76%
of 29 ratingsMore ALNY News
Freedom Capital upgraded Alnylam (ALNY) to Buy from Hold with a price target of $410, down from $470. The company’s Amvuttra continues to post “exceptional” rev...
In February 2026, Alnylam Pharmaceuticals reported its fourth-quarter and full-year 2025 results, showing revenue rising to US$1.10 billion for the quarter and...
If you are wondering whether Alnylam Pharmaceuticals at around US$308 per share still offers value, you are not alone. This article focuses squarely on what tha...
Alnylam Pharmaceuticals (ALNY) has disclosed a new risk, in the International Operations category. Alnylam Pharmaceuticals faces material execution risk in sca...
Alnylam Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the sto...
Advertisement What Alnylam’s latest earnings tell you Alnylam Pharmaceuticals (ALNY) just reported Q4 and full year 2025 results that moved from losses to pro...
Analyst Joseph Stringer of Needham maintained a Buy rating on Alnylam Pharma, reducing the price target to $510.00. Joseph Stringer has given his Buy rating du...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.